Literature DB >> 9419563

Cascade of metastatic colorectal carcinoma from the liver to the anterior diaphragmatic lymph nodes.

N J Graham1, H I Libshitz.   

Abstract

RATIONALE AND
OBJECTIVES: Metastases of colon carcinoma from the liver to porta hepatis and celiac axis lymph nodes constitute a contraindication to hepatic metastatic resection. Our objective was to determine the frequency of anterior diaphragmatic lymph node (ADLN) enlargement, another efferent pathway of hepatic lymphatic drainage, in patients with colon carcinoma.
METHODS: Abdominal computed tomography scans from 50 patients with colon carcinoma in whom hepatic metastases were either present (n = 25) or absent (n = 25) were reviewed. ADLNs greater than or equal to 5 mm were considered enlarged.
RESULTS: Thirteen of 25 patients with hepatic metastases had ADLNs greater than or equal to 5 mm; three of 25 patients without hepatic metastases had ADLNs greater than or equal to 5 mm. The difference was statistically significant (p = .002).
CONCLUSION: Metastases of colon carcinoma from the liver to the ADLNs probably are not rare. ADLN involvement would obviate hepatic resection. The ADLNs should be assessed preoperatively in surgical candidates with hepatic metastases of colon carcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 9419563     DOI: 10.1016/s1076-6332(05)80185-0

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  2 in total

1.  Extrapleural and cardiophrenic lymph nodes: prevalence, clinical significance and diagnostic value.

Authors:  Beatrice Feragalli; Cesare Mantini; Nicoletta Civitareale; Roberta Polverosi; Armando Tartaro; Antonio Raffaele Cotroneo
Journal:  Radiol Med       Date:  2013-11-19       Impact factor: 3.469

2.  Characterization of Antigen-Presenting Cell Subsets in Human Liver-Draining Lymph Nodes.

Authors:  Patrick P C Boor; Brenda M Bosma; Khe T C Tran; Luc J W van der Laan; Hanneke Hagenaars; Jan N M IJzermans; Herold J Metselaar; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.